Zentrela, Inc., a leading Canadian AI neurotechnology company, has announced more results of a groundbreaking study with Kinloch Wellness Ltd., a pioneer in non-psychoactive, plant-based health and wellness products.
The study set out to objectively quantify the efficacy of two CBD products in enhancing the relaxation state of study subjects. Zentrela’s AI-powered wearable EEG devices analyzed brain activity (EEG) of consumers before and after consuming both CBD products, assessing changes in their relaxation mental state.
The study revealed that one CBD product was significantly more effective in promoting relaxation. This product, which contains 50mg of CBD and terpenes—fragrant oils found in plants like cannabis known to amplify certain cannabinoid effects—stood out as particularly impactful. Read the scientific article here.
Another key finding was that a single gummy of this effective CBD product significantly increased relaxation in female participants, with a 3X greater effect compared to males.
This evidence highlights how contrasting the efficacy of a dose is due to human variability. While the study does not definitively attribute the difference to gender, factors such as BMI associated with gender may explain why the same dosage did not yield similar results in males.
“It’s well-known that terpenes enhance cannabinoid effects and that individual factors like gender or BMI may influence dosage efficacy. The real breakthrough here is our ability to objectively measure these effects at a speed and cost-effective way that is enabling wellness CPG companies to reliably test their products and then use this scientific and objective evidence to educate health practitioners, retailers and end consumers” said Israel Gasperin, Engineering Scientist and CEO of Zentrela, Inc.
Said Dwayne Stewart, CEO of Kinloch Wellness, “Zentrela has allowed us to give data-based insights into the performance of our products for both medical professionals and recreational sellers of our products, enhancing their access to information about how our products may perform for their patients and clients.”
For complete results and detailed information about the study methodology, please visit zentrela.com/publication/cusic-25.
Show Comments